Literature DB >> 31841644

Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males.

Katharine E Secunda1, Jennifer S Guimbellot2, Borko Jovanovic1, Sonya L Heltshe3, Scott D Sagel4, Steven M Rowe2, Manu Jain1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31841644      PMCID： PMC7159427          DOI： 10.1164/rccm.201909-1845LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  10 in total

1.  Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis.

Authors:  Sanjay H Chotirmall; Stephen G Smith; Cedric Gunaratnam; Sonya Cosgrove; Borislav D Dimitrov; Shane J O'Neill; Brian J Harvey; Catherine M Greene; Noel G McElvaney
Journal:  N Engl J Med       Date:  2012-05-20       Impact factor: 91.245

2.  Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.

Authors:  Steven M Rowe; Sonya L Heltshe; Tanja Gonska; Scott H Donaldson; Drucy Borowitz; Daniel Gelfond; Scott D Sagel; Umer Khan; Nicole Mayer-Hamblett; Jill M Van Dalfsen; Elizabeth Joseloff; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2014-07-15       Impact factor: 21.405

3.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Authors:  Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

4.  Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor.

Authors:  Meredith C Fidler; Jack Beusmans; Paul Panorchan; Fredrick Van Goor
Journal:  J Cyst Fibros       Date:  2016-10-20       Impact factor: 5.482

5.  Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.

Authors:  Jennifer L Taylor-Cousar; Anne Munck; Edward F McKone; Cornelis K van der Ent; Alexander Moeller; Christopher Simard; Linda T Wang; Edward P Ingenito; Charlotte McKee; Yimeng Lu; Julie Lekstrom-Himes; J Stuart Elborn
Journal:  N Engl J Med       Date:  2017-11-03       Impact factor: 91.245

6.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Authors:  Claire E Wainwright; J Stuart Elborn; Bonnie W Ramsey; Gautham Marigowda; Xiaohong Huang; Marco Cipolli; Carla Colombo; Jane C Davies; Kris De Boeck; Patrick A Flume; Michael W Konstan; Susanna A McColley; Karen McCoy; Edward F McKone; Anne Munck; Felix Ratjen; Steven M Rowe; David Waltz; Michael P Boyle
Journal:  N Engl J Med       Date:  2015-05-17       Impact factor: 91.245

7.  Gender differences in outcomes of patients with cystic fibrosis.

Authors:  Cayce L Harness-Brumley; Alan C Elliott; Daniel B Rosenbluth; Deepa Raghavan; Raksha Jain
Journal:  J Womens Health (Larchmt)       Date:  2014-12       Impact factor: 2.681

8.  17beta-Estradiol inhibits Ca2+-dependent homeostasis of airway surface liquid volume in human cystic fibrosis airway epithelia.

Authors:  Ray D Coakley; Hengrui Sun; Lucy A Clunes; Julia E Rasmussen; James R Stackhouse; Seiko F Okada; Ingrid Fricks; Steven L Young; Robert Tarran
Journal:  J Clin Invest       Date:  2008-11-20       Impact factor: 14.808

9.  Estrogen aggravates inflammation in Pseudomonas aeruginosa pneumonia in cystic fibrosis mice.

Authors:  Yufa Wang; Elvis Cela; Stéphane Gagnon; Neil B Sweezey
Journal:  Respir Res       Date:  2010-11-30

Review 10.  Sex differences in pharmacokinetics and pharmacodynamics.

Authors:  Offie P Soldin; Donald R Mattison
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447
  10 in total
  5 in total

1.  Caring for gender diverse youth with cystic fibrosis.

Authors:  Kacie M Kidd; Gina M Sequeira; Raina V Voss; Daniel J Weiner; Bonnie W Ramsey; Raksha Jain; Traci M Kazmerski
Journal:  J Cyst Fibros       Date:  2020-04-06       Impact factor: 5.482

2.  Update in Pediatrics 2020.

Authors:  Erick Forno; Steven H Abman; Jagdev Singh; Mary E Robbins; Hiran Selvadurai; Paul T Schumacker; Paul D Robinson
Journal:  Am J Respir Crit Care Med       Date:  2021-08-01       Impact factor: 30.528

3.  Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.

Authors:  David P Nichols; Alex C Paynter; Sonya L Heltshe; Scott H Donaldson; Carla A Frederick; Steven D Freedman; Daniel Gelfond; Lucas R Hoffman; Andrea Kelly; Michael R Narkewicz; Jessica E Pittman; Felix Ratjen; Margaret Rosenfeld; Scott D Sagel; Sarah Jane Schwarzenberg; Pradeep K Singh; George M Solomon; Michael S Stalvey; John P Clancy; Shannon Kirby; Jill M Van Dalfsen; Margaret H Kloster; Steven M Rowe
Journal:  Am J Respir Crit Care Med       Date:  2022-03-01       Impact factor: 30.528

4.  Sex differences in treatment patterns in cystic fibrosis pulmonary exacerbations.

Authors:  Kristina Montemayor; Kevin J Psoter; Noah Lechtzin; Sara W Carson; Christian A Merlo; Rebecca H Dezube; Kristin A Riekert; Sarah Allgood; Alexandra Toporek; Mark T Jennings; Natalie E West
Journal:  J Cyst Fibros       Date:  2021-06-03       Impact factor: 5.482

5.  Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators.

Authors:  Danya Muilwijk; Marlou Bierlaagh; Peter van Mourik; Jasmijn Kraaijkamp; Renske van der Meer; Rutger van den Bor; Harry Heijerman; René Eijkemans; Jeffrey Beekman; Kors van der Ent
Journal:  J Pers Med       Date:  2021-12-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.